Authors are requested to submit their valuable investigate at: or may ship as an e-mail attachment to the Editorial Office at [email protected] Conclusions: Golimumab doesn't appear in a position to maintain extended-phrase remission in UC in true lifestyle. The safety profile was excellent. Conclusions: The summary part of the manuscript https://www.directivepublications.org/journal-of-digestive-and-liver-diseases/